OOIR: Observatory of International Research

Papers

(The TQCC of Translational Neurodegeneration is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Retraction Note: Alpha-synuclein overexpression in the olfactory bulb initiates prodromal symptoms and pathology of Parkinson’s disease	387
Exploring the skin as an open window onto neurodegenerative diseases	341
Life and disease status of patients with Parkinson’s disease during and after zero-COVID in China: an online survey	207
Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer’s disease mouse model	190
Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington’s disease mice	166
N6-methyladenosine-modified circRIMS2 mediates synaptic and memory impairments by activating GluN2B ubiquitination in Alzheimer's disease	126
Retraction Note: Asiaticoside, a trisaccaride triterpene induces biochemical and molecular variations in brain of mice with parkinsonism	122
Impaired glymphatic function in the early stages of disease in a TDP-43 mouse model of amyotrophic lateral sclerosis	114
Oligodendrocyte progenitor cells in Alzheimer’s disease: from physiology to pathology	113
The C. elegans gba-3 gene encodes a glucocerebrosidase that exacerbates α-synuclein-mediated impairments in deletion mutants	108
Patient-derived iPSC models of Friedreich ataxia: a new frontier for understanding disease mechanisms and therapeutic application	101
Impaired dynamic interaction of axonal endoplasmic reticulum and ribosomes contributes to defective stimulus–response in spinal muscular atrophy	89
Attenuating α-synuclein pathology in mice with in situ engineered astrocytes	87
Gene therapy breakthroughs in ALS: a beacon of hope for 20% of ALS patients	84
CRISPR/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer’s disease	80
Age-dependent removal of Atg9-containing vesicle accumulations in motoneuron disease models by physical exercise	80
NLRP3 inflammasome in cognitive impairment and pharmacological properties of its inhibitors	74
Role of dopamine in the pathophysiology of Parkinson’s disease	73
Correction: A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau	72
A novel plasma p-tau181 assay as a specific biomarker of tau pathology in Alzheimer's disease	69
Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease	68
Defective mitophagy and the etiopathogenesis of Alzheimer’s disease	67
Dual modulation of amyloid beta and tau aggregation and dissociation in Alzheimer’s disease: a comprehensive review of the characteristics and therapeutic strategies	66
Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies	65
Correction: Olfactory swab sampling optimization for α-synuclein aggregate detection in patients with Parkinson’s disease	61

Cognitive dysfunction of patients infected with SARS-CoV-2 omicron variant in Shanghai, China	59
Remodeling of astrocyte secretome in amyotrophic lateral sclerosis: uncovering novel targets to combat astrocyte-mediated toxicity	58
Targeted delivery of BACE1 siRNA for synergistic treatment of Alzheimer's disease	58
Cortical layer multi-parameter analysis of neurovascular impairments in AD/ADRD rodent model with in vivo optical imaging	57
Hybrid nanostructures for neurodegenerative disease theranostics: the art in the combination of biomembrane and non-biomembrane nanostructures	56
Inflammasomes in neurodegenerative diseases	55
Immunosenescence in aging and neurodegenerative diseases: evidence, key hallmarks, and therapeutic implications	55
ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein	53
Therapeutics for neurodegenerative diseases by targeting the gut microbiome: from bench to bedside	52
Nose-to-brain drug delivery: from bench to bedside	52
Controversies and insights into PTBP1-related astrocyte-neuron transdifferentiation: neuronal regeneration strategies for Parkinson’s and Alzheimer’s disease	52
α-Synuclein oligomers potentiate neuroinflammatory NF-κB activity and induce Cav3.2 calcium signaling in astrocytes	51
Longitudinal evolution of cortical thickness signature reflecting Lewy body dementia in isolated REM sleep behavior disorder: a prospective cohort study	51
Microstructural integrity of the locus coeruleus and its tracts reflect noradrenergic degeneration in Alzheimer’s disease and Parkinson’s disease	51
Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease	50
Peripheral proteinopathy in neurodegenerative diseases	49
The emerging role of furin in neurodegenerative and neuropsychiatric diseases	49
Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer’s disease protects against mitochondrial dysfunction and mitigates brain pathology	49
A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter	48
Multidimensional biomarkers for multiple system atrophy: an update and future directions	46
An AARS1 variant identified to cause adult-onset leukoencephalopathy with neuroaxonal spheroids and pigmented glia	46
Perivascular spaces relate to the course and cognition of Huntington’s disease	46
Shared burden of ultra-rare genetic variants across a spectrum of motor neuron diseases	45
Targeting galectin-3 to counteract spike-phase uncoupling of fast-spiking interneurons to gamma oscillations in Alzheimer’s disease	43
Neuronal and synaptic adaptations underlying the benefits of deep brain stimulation for Parkinson's disease	41
Aging-dependent YAP1 reduction contributes to AD pathology by upregulating the Nr4a1-AKT/GSK-3β axis	37
Improving vulnerable Calbindin1− neurons in the ventral hippocampus rescues tau-induced impairment of episodic memory	37
SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system	37
Astrocytes contribute to toll-like receptor 2-mediated neurodegeneration and alpha-synuclein pathology in a human midbrain Parkinson’s model	37
Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer’s disease	37
Deficient AMPK-SENP1-Sirt3 signaling impairs mitochondrial complex I function in Parkinson’s disease model	36
TDP-43 dysregulation and neuromuscular junction disruption in amyotrophic lateral sclerosis	36
Role of extracellular vesicle-carried ncRNAs in the interactive ‘dialogue’ within the brain and beyond: emerging theranostic epigenetic modifiers in brain-derived nanoplatforms	36
Ultrasensitive detection of aggregated α-synuclein using quiescent seed amplification assay for the diagnosis of Parkinson’s disease	36
Metabolic regulation of microglial phagocytosis: Implications for Alzheimer's disease therapeutics	34
In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use	34
Cerebrospinal fluid cyclase-associated protein 2 is increased in Alzheimer’s disease and correlates with tau pathology	34
Extracellular PHF-tau modulates astrocyte mitochondrial dynamics and mediates neuronal connectivity	33
Axonal tau reduction ameliorates tau and amyloid pathology in a mouse model of Alzheimer’s disease	33
Plasma proteomic signatures as predictors of dementia risk in individuals with sleep apnea: a cohort study	31
Emerging role of senescent microglia in brain aging-related neurodegenerative diseases	31